<DOC>
	<DOCNO>NCT01831973</DOCNO>
	<brief_summary>INVESTIGATIONAL PRODUCT : TLC388 ( Lipotecan* ) *Lipotecan drug product TLC388 HCl . PHASE OF DEVELOPMENT : Phase II No . OF PATIENTS : Approximately 40 ( Stage I : 15 evaluable patient , Stage II : 25 evaluable patient ) STUDY OBJECTIVES : Primary • To evaluate non-progression disease ( non-PD ) rate end cycle 6 Secondary - To evaluate progression free survival ( PFS ) - To evaluate overall survival ( OS ) - To evaluate duration non-PD - To evaluate objective response rate ( ORR ; ORR= CR+PR ) duration - To evaluate safety profile TLC388 - To evaluate change health-related quality life ( HRQOL ) end cycle 6 STUDY DESIGN : This Phase II , open-label , single-arm , multi-centre study evaluate TLC388 monotherapy patient locally advance and/or metastatic renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>A Phase II Study Evaluate Efficacy Safety TLC388 Advanced/Metastatic RCC Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Adult patient define age ≥ 18 year Histologically confirm Renal cell carcinoma ( RCC ) Locally advance metastatic RCC . Locally advance RCC : define stage . . T3/T4 disease , amenable curative surgery radiation therapy , involvement renal vein/vena cava/peripelvic perirenal fat/adrenal gland , invasion beyond Gerota 's fascia ( Moch et al. , 2009 ) . Metastatic RCC : equivalent Stage IV RCC , accord American Joint Committee Cancer ( AJCC ) stag Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤ 2 . An ECOG ≤ 1 patient failure &gt; = 2 prior target therapy acceptable Documented RCC disease measurable nonmeasurable lesion image RECIST v1.1 ( Response Evaluation Criteria Solid Tumors ) criterion Documented treatment failure least 1 prior target therapy ( sorafenib , sunitinib pazopanib VEGF TKI , bevacizumab , temsirolimus , everolimus mTOR inhibitor ) advance metastatic RCC . If treatmentnaïve , . patient poor prognosis feature accord Memorial SloanKettering Cancer Centre ( MSKCC ) risk criterion acceptable Any acute chronic adverse effect prior therapy resolve &lt; Grade 2 determine CTCAE v4.0 criterion Laboratory value screen : Absolute neutrophil count ≥ 1,500 /mm3 ; Platelets ≥ 100,000 /mm3 ; Hemoglobin ≥ 9.0 g/dL ; Total bilirubin ≤ 1.5 time upper limit normal ; AST ( SGOT ) ≤ 2.5 time upper limit normal ; ALT ( SGPT ) ≤ 2.5 time upper limit normal ; Serum creatinine ≤ 2 time upper limit normal ; Pregnancy lactation . Women childbearing potential must negative serum pregnancy test within 7 day prior enrolment . Male female patient childbearing potential must agree use appropriate birth control ( barrier method spermicide , oral parenteral contraceptive and/or intrauterine device ) entire duration study , patient must surgically sterile ( documentation patient 's medical record ) Receipt chemotherapy RCC Had cardiac angioplasty stenting event , myocardial infarction unstable angina within 3 month study entry Persistent QTc &gt; 450 m male , &gt; 470 m female , accord Fridericia 's correction Patients Grade 3 great hyponatremia screen History Class III IV congestive heart failure accord New York Heart Association ( NYHA ) classification History another malignancy , except nonbasalcell carcinoma skin carcinomainsitu uterine cervix , disease free ≥5 year History presence central nervous system ( CNS ) metastasis leptomeningeal tumor document CT MRI scan , analysis cerebrospinal fluid neurological exam History human immunodeficiency virus infection Presence active , uncontrolled infection Radiotherapy receive within 4 week prior baseline Use investigational agent within 4 week baseline Major surgery within 4 week prior baseline Receipt radiotherapy &gt; 25 % bone marrow Concomitant treatment , anticipate use , pharmaceutical herbal agent potent inhibitor inducer cytochrome P450 enzyme ( Appendix D1 ) , unless approve Sponsor Uncontrolled intercurrent illness would jeopardize patient safety , interfere objective protocol , limit patient compliance study requirement , determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>